Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.

C Röllig; M Kramer; M Gabrecht; M Hänel; R Herbst; U Kaiser; N Schmitz; J Kullmer; S Fetscher; H Link; L Mantovani-Löffler; U Krümpelmann; T Neuhaus; F Heits; H Einsele; B Ritter; M Bornhäuser; J Schetelig; C Thiede; B Mohr; M Schaich; U Platzbecker; Kerstin Schäfer-Eckart; A Krämer; W E Berdel; H Serve; G Ehninger; U S Schuler

doi:10.1093/annonc/mdy030

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.

C Röllig
, M Kramer
, M Gabrecht
, M Hänel
, R Herbst
, U Kaiser
, N Schmitz
, J Kullmer
, S Fetscher
, H Link
, L Mantovani-Löffler
, U Krümpelmann
, T Neuhaus
, F Heits
, H Einsele
, B Ritter
, M Bornhäuser
, J Schetelig
, C Thiede
, B Mohr

M Schaich, U Platzbecker, Kerstin Schäfer-Eckart (Co-author), A Krämer, W E Berdel, H Serve, G Ehninger, U S Schuler

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Original Article › peer-review

30 Citations (Web of Science)

Original language	English
Pages (from-to)	973-978
Journal	ANNALS OF ONCOLOGY
Volume	29
Issue number	4
DOIs	https://doi.org/10.1093/annonc/mdy030
Publication status	Published - 2018

Keywords

REAL-WORLD
ADULTS
CHEMOTHERAPY
DIAGNOSIS
CANCER
AGE

Access to Document

10.1093/annonc/mdy030

Cite this

Röllig, C., Kramer, M., Gabrecht, M., Hänel, M., Herbst, R., Kaiser, U., Schmitz, N., Kullmer, J., Fetscher, S., Link, H., Mantovani-Löffler, L., Krümpelmann, U., Neuhaus, T., Heits, F., Einsele, H., Ritter, B., Bornhäuser, M., Schetelig, J., Thiede, C., ... Schuler, U. S. (2018). Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. ANNALS OF ONCOLOGY , 29(4), 973-978. https://doi.org/10.1093/annonc/mdy030

Röllig, C ; Kramer, M ; Gabrecht, M et al. / Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. In: ANNALS OF ONCOLOGY 2018 ; Vol. 29, No. 4. pp. 973-978.

@article{3ff433a637b94dfdac7307fe445350ce,

title = "Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.",

keywords = "REAL-WORLD, ADULTS, CHEMOTHERAPY, DIAGNOSIS, CANCER, AGE",

author = "C R{\"o}llig and M Kramer and M Gabrecht and M H{\"a}nel and R Herbst and U Kaiser and N Schmitz and J Kullmer and S Fetscher and H Link and L Mantovani-L{\"o}ffler and U Kr{\"u}mpelmann and T Neuhaus and F Heits and H Einsele and B Ritter and M Bornh{\"a}user and J Schetelig and C Thiede and B Mohr and M Schaich and U Platzbecker and Kerstin Sch{\"a}fer-Eckart and A Kr{\"a}mer and Berdel, \{W E\} and H Serve and G Ehninger and Schuler, \{U S\}",

note = "Sch{\"a}fer-Eckart, K: Department for Internal Medicine 5, Paracelsus Medical University, N{\"u}rnberg, Germany.",

year = "2018",

doi = "10.1093/annonc/mdy030",

language = "English",

volume = "29",

pages = "973--978",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

number = "4",

}

Röllig, C, Kramer, M, Gabrecht, M, Hänel, M, Herbst, R, Kaiser, U, Schmitz, N, Kullmer, J, Fetscher, S, Link, H, Mantovani-Löffler, L, Krümpelmann, U, Neuhaus, T, Heits, F, Einsele, H, Ritter, B, Bornhäuser, M, Schetelig, J, Thiede, C, Mohr, B, Schaich, M, Platzbecker, U, Schäfer-Eckart, K, Krämer, A, Berdel, WE, Serve, H, Ehninger, G & Schuler, US 2018, 'Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.', ANNALS OF ONCOLOGY , vol. 29, no. 4, pp. 973-978. https://doi.org/10.1093/annonc/mdy030

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. / Röllig, C; Kramer, M; Gabrecht, M et al.
In: ANNALS OF ONCOLOGY , Vol. 29, No. 4, 2018, p. 973-978.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.

AU - Röllig, C

AU - Kramer, M

AU - Gabrecht, M

AU - Hänel, M

AU - Herbst, R

AU - Kaiser, U

AU - Schmitz, N

AU - Kullmer, J

AU - Fetscher, S

AU - Link, H

AU - Mantovani-Löffler, L

AU - Krümpelmann, U

AU - Neuhaus, T

AU - Heits, F

AU - Einsele, H

AU - Ritter, B

AU - Bornhäuser, M

AU - Schetelig, J

AU - Thiede, C

AU - Mohr, B

AU - Schaich, M

AU - Platzbecker, U

AU - Schäfer-Eckart, Kerstin

AU - Krämer, A

AU - Berdel, W E

AU - Serve, H

AU - Ehninger, G

AU - Schuler, U S

N1 - Schäfer-Eckart, K: Department for Internal Medicine 5, Paracelsus Medical University, Nürnberg, Germany.

PY - 2018

Y1 - 2018

KW - REAL-WORLD

KW - ADULTS

KW - CHEMOTHERAPY

KW - DIAGNOSIS

KW - CANCER

KW - AGE

U2 - 10.1093/annonc/mdy030

DO - 10.1093/annonc/mdy030

M3 - Original Article

C2 - 29390048

SN - 0923-7534

VL - 29

SP - 973

EP - 978

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

IS - 4

ER -

Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U et al. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. ANNALS OF ONCOLOGY . 2018;29(4):973-978. doi: 10.1093/annonc/mdy030